Berberine Side Effects and Safety: What to Know
The reported side effects are mainly gastrointestinal. Here is the full list, who should avoid berberine, and what the current EU position adds to that.
The side effects reported for berberine in research are mainly gastrointestinal: nausea, abdominal pain, bloating, constipation or diarrhoea. It is not suitable during pregnancy or breastfeeding, or for infants, children and adolescents. Anyone taking prescription medicine should check with a pharmacist first. The wider EU safety position is genuinely unsettled, and that is set out further down.
Key takeaways
- NCCIH describes reported side effects as "primary gastrointestinal symptoms such as nausea, abdominal pain, bloating, constipation, or diarrhea", and LiverTox describes them as largely mild and transient.
- Berberine is not suitable for pregnant or breastfeeding women, or for infants, children and adolescents.
- Anyone on prescription medicine should speak to a pharmacist before starting. An interaction with cyclosporine is documented.
- EFSA's January 2026 draft opinion could not establish a safe intake for humans and cites laboratory evidence of genotoxicity. It is a draft under consultation, not a ban, with a final opinion expected in early 2027.
- Belgium caps isoquinoline alkaloids, expressed as berberine, at 10 mg a day. Ireland has not set an equivalent limit at the time of writing.
On this page
The side effects actually reported
The clearest consumer-facing summary comes from NCCIH, part of the US National Institutes of Health. It states that "some side effects of berberine have been reported in research studies, primarily gastrointestinal symptoms such as nausea, abdominal pain, bloating, constipation, or diarrhea".
The NIH LiverTox database describes them in similar terms: "few and largely mild and transient gastrointestinal symptoms of nausea, abdominal bloating, diarrhea or constipation".
| What is reported | How it is described |
|---|---|
| Nausea | Gastrointestinal, described as largely mild and transient |
| Abdominal pain | Gastrointestinal, reported in research studies |
| Bloating | Gastrointestinal, described as largely mild and transient |
| Constipation | Gastrointestinal, described as largely mild and transient |
| Diarrhoea | Gastrointestinal, described as largely mild and transient |
| Interaction with cyclosporine | Documented by NCCIH, a medicine used after organ transplant |
One caveat belongs with that list. Most of the human studies were small and short, and trials usually exclude the people most likely to run into trouble, including pregnant women and people taking several medicines. Few reported side effects in a small trial is not the same as evidence of safety.
Who should avoid berberine
- Pregnant or breastfeeding women. NCCIH states berberine "is likely to be unsafe for infants and may also be unsafe for use during pregnancy or while breastfeeding". See our guide on berberine in pregnancy and breastfeeding.
- Infants, children and adolescents. NCCIH links berberine exposure to a harmful buildup of bilirubin in infants, and ANSES advises children and adolescents to avoid berberine-containing food supplements.
- Anyone taking prescription medicines. NCCIH documents an interaction with cyclosporine, and berberine may inhibit CYP3A4 and possibly other CYP450 enzymes, which are involved in clearing many medicines. See berberine and medicines.
- Anyone living with a medical condition, including a liver condition, who should raise it with their GP or pharmacist before using any supplement.
That is not a complete list, and it is no substitute for advice about your own circumstances.
When to speak to a pharmacist or GP
A pharmacist is the quickest route to a proper answer. You need no appointment and no fee, they can see your dispensing history if you use the same pharmacy, and they have access to interaction databases that are updated continuously. Bring the product or a photo of the full label, plus a list of everything else you take.
Speak to someone before you start if you take any prescription medicine, if you have a diagnosed condition, or if you are pregnant, breastfeeding or planning a pregnancy. Speak to your GP during use if something you experience while taking any supplement concerns you.
The wider picture: EFSA's 2026 draft opinion
On 29 January 2026 EFSA's Panel on Nutrition, Novel Foods and Food Allergens endorsed a draft scientific opinion on the safety of plant preparations containing berberine, under Article 8(2) of Regulation (EC) No 1925/2006. A public consultation opened on 3 March 2026, was later extended, and closed on 10 July 2026. A final opinion is expected in early 2027.
Two conclusions from that draft, quoted in the papers of the UK Committee on Toxicity, are worth reading in full:
"The available data do not allow establishing a safe intake for humans for any preparations of the plant species, and plant parts thereof, included in the assessment."
"There is evidence for berberine genotoxicity in vitro, indicating gene mutation and chromosomal damage, which are supported by mechanistic evidence."
The species covered include Berberis aristata, the source used for most berberine HCl supplements, so this is not a distant concern about some other plant. Our guide to what berberine is covers that species in more detail.
How to read that accurately
- "Could not establish a safe intake" is not "proven harmful." Data gaps drive that conclusion as much as findings of harm do.
- "In vitro" means in laboratory systems, such as cultured cells, not in people. It is a serious flag that triggers further work, not a measurement of risk to an individual.
- A draft opinion is not law, and it should not be waved away either. Nothing has been banned, but "no safe intake could be established" is not a routine finding from the EU's scientific authority on food safety.
Why Belgium set a 10 mg limit
Some member states acted before the EU-level assessment reported. According to ANSES, the French food safety agency, Belgium has set a maximum daily dose of 10 mg for berberine in food supplements, expressed as isoquinoline alkaloids. Poland is reported to apply the same limit, although we could not confirm that against a primary Polish regulatory text.
That figure sits far below the serving sizes typically sold across the EU, so in practice it removes conventional berberine supplements from those markets. Ireland has not set an equivalent limit at the time of writing. Member states taking visibly different positions is itself a signal that the science is not agreed. For how serving sizes vary between brands, see berberine supplement strengths.
How the different sources compare
The authorities do not fully agree, and it is more useful to see that than to have it smoothed over. On the liver, for example, the EFSA draft flags idiosyncratic herb-induced injury among its concerns, while LiverTox gives berberine a likelihood score of "E (unlikely cause of clinically apparent liver injury)". Those positions are not necessarily contradictory: LiverTox is summarising an absence of reported cases, and the draft is assessing a hazard where the data are thin. Anyone with a liver condition should raise it with their GP.
| Source | Status of the document | What it says |
|---|---|---|
| NCCIH (US NIH) | Published consumer information | Side effects primarily gastrointestinal. Interaction with cyclosporine. Likely unsafe for infants; may be unsafe in pregnancy or breastfeeding. |
| EFSA NDA Panel | Draft opinion, 29 January 2026; consultation closed 10 July 2026; final opinion expected early 2027 | No safe intake for humans could be established for any preparation assessed. Evidence of genotoxicity in vitro. Significant data gaps. |
| Belgium (Poland reported to follow) | National limit in force | Maximum 10 mg per day of isoquinoline alkaloids, expressed as berberine. |
| NIH LiverTox | Published database entry | Likelihood score E, unlikely cause of clinically apparent liver injury, noting few detailed prospective human studies. |
| ANSES (France) | Published opinion | Advises children and adolescents, pregnant and breastfeeding women and certain vulnerable groups to avoid berberine supplements. |
What Irish supplement labels must tell you
Food supplements are regulated in Ireland as food, not as medicines. The Food Safety Authority of Ireland requires every label to carry a warning not to exceed the stated recommended daily dose, a statement that supplements should not be used as a substitute for a varied diet, and a statement that the product should be stored out of the reach of young children. Labelling must not attribute to a supplement "the property of preventing, treating or curing a human disease".
Serving sizes and compositions differ widely between brands, so the label is the only reliable place to check what you have. For this site's supplement, the ingredient and serving information is set out on the berberine product page, and the physical label is the authoritative version. Our guide to reading food supplement labels in Ireland covers the rest of the panel.
Frequently asked questions
Are the reported side effects serious?
The side effects documented in research are mainly gastrointestinal: nausea, abdominal pain, bloating, constipation or diarrhoea. NCCIH and LiverTox both describe them as largely mild and transient. The limitation is that the human studies were generally small and short, so they could not detect uncommon or delayed effects. Absence of reported harm in small trials is not evidence of safety.
Has berberine been banned in the EU?
No. EFSA published a draft scientific opinion in January 2026 that could not establish a safe intake for humans, and that draft went through a public consultation which closed on 10 July 2026. A draft opinion is a scientific document, not a legal measure. A final opinion is expected in early 2027, and any EU-wide restriction would be a separate decision taken afterwards by risk managers.
What does "genotoxicity in vitro" actually mean?
In vitro means the tests were carried out in laboratory systems such as cultured cells or bacterial assays, not in people or animals. The draft reports evidence indicating gene mutation and chromosomal damage in those systems, supported by mechanistic evidence, and notes that confirmation in living organisms is needed. It is a signal that requires further investigation rather than a measurement of risk to an individual.
Can I take berberine with my prescription medicines?
That is a question for your pharmacist, not for an article. NCCIH documents an interaction with cyclosporine, and berberine may inhibit CYP3A4 and possibly other CYP450 enzymes, which is a broad theoretical scope because many medicines are handled by those enzymes. Bring a full list of everything you take, including over-the-counter products, and the supplement label itself.
Is berberine safe in pregnancy or while breastfeeding?
It is not suitable. NCCIH states berberine "is likely to be unsafe for infants and may also be unsafe for use during pregnancy or while breastfeeding", citing a harmful buildup of bilirubin in infants which can cause brain damage. ANSES also advises pregnant and breastfeeding women to avoid berberine supplements. Anyone who is pregnant, breastfeeding or planning a pregnancy should speak to their GP, midwife or pharmacist.
What should I do if I get stomach upset while taking it?
Stop and speak to a pharmacist or your GP, bringing the product or a photo of the label with you. Do not exceed the stated recommended daily dose in the meantime, and follow the directions on the physical label. If any symptom is severe, persistent or worrying, contact your GP rather than waiting to see whether it settles.
Sources and further reading
- National Center for Complementary and Integrative Health (NIH). Berberine and Weight Loss: What You Need To Know. Accessed 13 August 2026.
- Committee on Toxicity (UK). Draft Scientific Opinion on the safety of plant preparations containing berberine, reproducing the draft conclusions. Accessed 13 August 2026.
- EFSA. Targeted stakeholder meeting on the draft Opinion on plant preparations containing berberine. Accessed 13 August 2026.
- ANSES. Use of berberine-containing plants in food supplements. Accessed 13 August 2026.
- LiverTox, National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Berberine. Accessed 13 August 2026.
- Food Safety Authority of Ireland. Food Supplements. Accessed 13 August 2026.